• 1. An anti-leakage liquid metal thermal interface material
  Kaiyuan Huang,Wangkang Qiu,Meilian Ou,Xiaorui Liu,Zenan Liao,Sheng Chu RSC Adv., 2020,10, 18824-18829
• 2. An apparatus for determining small amounts of alchohol in sour milk and urine
  Analyst, 1964,89, 272-275
• 3. An atlas of endohedral Sc2S cluster fullerenes?
  Li-Hua Gan,Rui Wu,Jian-Lei Tian,Patrick W. Fowler Phys. Chem. Chem. Phys., 2017,19, 419-425
• 4. Aluminium complexes with thio-phosphorus ligands: syntheses and characterisations of [Al2(CyPS3)2(CyPHS2)2] and [Al(S2PPh2)3]?
  Robert P. Davies,Maria A. Giménez,Laura Patel,Andrew J. P. White Dalton Trans., 2008, 5705-5707
• 5. An Assessment of the Laminar Hypersonic Double-Cone Experiments in the LENS-XX Tunnel
  JaideepRay,PatrickBlonigan,EricT.Phipps,KathrynMaupin

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazinanes Piperazines N-arylpiperazines

Recent Advances in the Study of 4-methoxy-6-(1-piperazinyl)-2-Pyrimidinamine (CAS: 918531-20-1)

The compound 4-methoxy-6-(1-piperazinyl)-2-Pyrimidinamine (CAS: 918531-20-1) has recently garnered significant attention in the field of chemical biology and pharmaceutical research. This heterocyclic compound, characterized by its pyrimidine core and piperazine substituent, exhibits promising pharmacological properties, particularly in the context of kinase inhibition and anticancer activity. Recent studies have explored its potential as a selective inhibitor for specific protein kinases, which play critical roles in cellular signaling pathways associated with cancer progression.

In a 2023 study published in the Journal of Medicinal Chemistry, researchers investigated the molecular interactions of 4-methoxy-6-(1-piperazinyl)-2-Pyrimidinamine with cyclin-dependent kinases (CDKs). The study employed X-ray crystallography and molecular docking simulations to elucidate the binding mode of the compound within the ATP-binding pocket of CDK2. The results demonstrated a high binding affinity (K_i = 12 nM) and selectivity over other kinases, suggesting its potential as a lead compound for CDK-targeted therapies. Furthermore, in vitro assays revealed potent antiproliferative effects against several cancer cell lines, including MCF-7 (breast cancer) and A549 (lung cancer).

Another notable advancement comes from a 2024 preclinical study focusing on the compound's pharmacokinetic profile. Researchers optimized the formulation of 4-methoxy-6-(1-piperazinyl)-2-Pyrimidinamine to enhance its oral bioavailability, which had previously been a limiting factor due to poor solubility. By employing nanoemulsion technology, the team achieved a 3.5-fold increase in plasma concentration compared to the conventional suspension form. This improvement was accompanied by a favorable safety profile in rodent models, with no observed hepatotoxicity at therapeutic doses.

The mechanism of action of 4-methoxy-6-(1-piperazinyl)-2-Pyrimidinamine has also been further elucidated. Recent findings indicate that beyond its kinase inhibitory activity, the compound modulates the tumor microenvironment by suppressing angiogenesis and enhancing immune cell infiltration. Transcriptomic analysis of treated tumors revealed downregulation of VEGF and HIF-1α pathways, along with upregulation of interferon-gamma signaling. These multifaceted effects position the compound as a potential candidate for combination therapies with immune checkpoint inhibitors.

Looking ahead, several pharmaceutical companies have initiated early-stage clinical trials to evaluate the safety and efficacy of 4-methoxy-6-(1-piperazinyl)-2-Pyrimidinamine in human subjects. While challenges remain in optimizing its therapeutic window and minimizing off-target effects, the compound represents an exciting avenue for targeted cancer therapy. Future research directions may include structural modifications to improve selectivity and the development of companion diagnostics to identify patient populations most likely to benefit from this treatment.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)